<DOC>
	<DOCNO>NCT00558038</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness experimental drug AST-120 compare lactulose patient mild hepatic encephalopathy .</brief_summary>
	<brief_title>Safety Efficacy AST-120 Compared Lactulose Patients With Hepatic Encephalopathy</brief_title>
	<detailed_description>This multi-center , open-label , four week trial compare AST-120 lactulose patient mild ( Stage 1-2 ) hepatic encephalopathy . Patients randomize two group : - Lactulose - AST-120 Patients meet inclusion criterion take either AST-120 lactulose 4 week ( 28 day ) . AST-120 distribute 2 gram sachet take four time daily . Lactulose take formulation , dose frequency previously prescribe individual patient . Lactulose naïve patient randomize lactulose receive initial dose 30cc twice day . The dose titrate discretion investigator patient experience 2-3 soft stool per day . Patients randomize AST-120 receive 2 gram four time day duration study . Titration AST-120 NOT allow . Patients evaluate throughout study efficacy safety . A follow-up visit schedule 1 week end 4 week treatment period .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<criteria>Patients End Stage Liver Disease secondary cause ( patient undergo portosystemic shunting ( TIPS ) procedure &gt; 3 month prior randomization include ) Lactulose naïve patient patient currently establish dose lactulose MELD score ≤ 15 ( MELD score 20 allowable remain stable least 3 month ) Meet criterion Stage 12 hepatic encephalopathy accord Westhaven Scale Patients must discontinue rifaximin oral antibiotic least 48 hour prior randomization Able willing comply protocol procedure plan duration study Able willing understand , sign date inform consent document , authorize access protect health information Have person ( spouse , relative , friend ) willing accompany patient study visit ( patient condition recommend drive vehicle ) Females must postmenopausal , surgically incapable bearing child , practice reliable method birth control ( intrauterine device , spermicide barrier ) . Partner/spouse sterility may also qualify investigator 's discretion . Females childbearing potential must negative urine pregnancy test baseline . Note : Patients already lactulose randomize AST120 stop take lactulose day begin take AST120 . Patients whose condition necessitate continuous administration antibiotic ( e.g . rifaximin , neomycin , metronidazole ) Patients undergoing chemotherapy treatment cancer ( patient hepatocellular carcinoma treat method chemotherapy may enrol ) Patients require continued treatment narcotic sedatives Patients active GI bleeding Patients active infection Patients sign symptom severe dehydration Poor tolerability venipuncture lack adequate venous access require blood sample Unable attend visit require protocol Female patient must EXCLUDED pregnant , breast feeding , plan become pregnant study use hormonal contraception method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hepatic</keyword>
	<keyword>Encephalopathy</keyword>
	<keyword>Liver</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>Liver Failure</keyword>
	<keyword>Lactulose</keyword>
	<keyword>AST-120</keyword>
</DOC>